# A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

> **NCT00269724** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 250 (—)

## Conditions studied

- Urinary Incontinence

## Interventions

- **DRUG:** OROS® oxybutynin

## Key facts

- **NCT ID:** NCT00269724
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** —
- **Final completion:** 1997-09
- **Target enrollment:** 250 (—)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269724, "A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00269724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*